Recipient(s) will receive an email with a link to 'Anticoagulation DNA Panel' and will have access to the topic for 7 days.
Subject: Anticoagulation DNA Panel
(Optional message may have a maximum of 1000 characters.)
The anticoagulation DNA panel tests for genetic variants in the CYP2C9 and VKORC1 genes that account for >50% of variation in warfarin response. Genotyping may reduce the need for INR surveillance as genotype-based dosing regimens are established.
Variants tested by the anticoagulation panel include
CYP2C9 *1 (normal)
CYP2C9 *2 (c.430C>T; Arg144Cys)
CYP2C9 *3 (c.1075A>C; Ile359Leu)
VKORC1 *1 (normal)
VKORC1 *2 promoter variant (c.–1639G>A)
Initiating warfarin (Coumadin) therapy
Optimizing dosing for warfarin
The results of a genetic test may be affected by DNA rearrangements, blood transfusion, bone marrow transplantation, or rare sequence variations.